AZD5213

DRUG5 trials

Sponsors

AstraZeneca

Conditions

Brain Distribution of [11C]AZ12807110 and AZD5213HealthyMild Alzheimer's DiseaseMild Cognitive ImpairmentTolerability

Phase 1

Study to Investigate Single Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects

CompletedNCT01121302

AstraZenecaTolerability

Start: 2010-05-31End: 2010-12-31Updated: 2015-01-28

Study to Investigate Multiple Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects

CompletedNCT01171105

AstraZenecaHealthy

Start: 2010-07-31End: 2011-05-31Updated: 2015-01-28

Evaluation of Histamine H3 Receptor Radioligand [11C]AZ12807110 and Histamine H3 Receptor Occupancy of AZD5213 After Oral Administration

CompletedNCT01194986

AstraZenecaBrain Distribution of [11C]AZ12807110 and AZD5213

Start: 2010-11-30End: 2011-06-30Updated: 2015-01-28

Assess the Safety, Tolerability and Pharmacokinetics of AZD5213 After Single and Multiple Ascending Oral Doses in Healthy Young and Elderly Japanese Subjects

CompletedNCT01335451

AstraZenecaHealthy

Start: 2011-04-30End: 2011-10-31Updated: 2015-01-28

Phase 2

A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment

CompletedNCT01548287

AstraZenecaMild Alzheimer's Disease, Mild Cognitive Impairment

Start: 2012-04-30End: 2013-01-31Updated: 2017-02-07